{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:58:09Z","timestamp":1776067089550,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020536","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020536","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium glucose co-transporter-2 inhibitors (SGLT2i) improve outcomes of patients with heart failure (HF). Urinary tract infections (UTI) are relatively common in HF, and their occurrence has been associated with an increased mortality risk. The use of SGLT2i has been associated with the occurrence of UTIs and mycotic genitourinary infections (MGI) which are a major cause of treatment discontinuation. This study aimed to study genitourinary infections in men and women with HF, their association with outcomes, and the impact of empagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analysis of EMPEROR-Pooled including a total of 9718 patients across the spectrum of ejection fraction. Descriptive statistics, Cox and time-varying survival models were used. The median follow-up time was 21 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Throughout follow-up, 757 (7.8%) patients experienced a lower UTI, 60 (0.6%) MGI, and 41 pyelonephritis\/urosepsis (0.4%). Genitourinary infections were more frequent in women than in men. Compared to patients without UTI\/MGI, those with pyelonephritis\/urosepsis were older and had higher comorbidity burden, whereas those with MGI were younger and had a higher prevalence of diabetes and obesity. Compared to placebo, empagliflozin was associated with a higher risk of lower UTI and MGI, particularly balanitis in men, but not pyelonephritis\/urosepsis. The risk of death increased after UTI, but not after MGI. The effect of empagliflozin versus placebo on the composite of HF hospitalization or cardiovascular death was not modified by the occurrence of genitourinary infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lower UTIs were relatively frequent in HF patients, whereas MGI and pyelonephritis\/urosepsis were infrequent. SGLT2i increased the risk of lower UTI and MGI. Although UTI, but not MGI, were associated with a higher subsequent risk of death, the clinical benefits of SGLT2i were preserved regardless of genitourinary infection occurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag054","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:38:01Z","timestamp":1772195881000},"source":"Crossref","is-referenced-by-count":1,"title":["Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto , Alameda Prof. Hern\u00e2ni Monteiro, Porto 4200-319 ,","place":["Portugal"]},{"name":"Centre d'Investigations Cliniques, Universit\u00e9 de Lorraine, Inserm, Plurith\u00e9matique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques, Universit\u00e9 de Lorraine, Inserm, Plurith\u00e9matique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-6933","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]},{"name":"University of Mississippi , Jackson, MS ,","place":["USA"]}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital , Athens ,","place":["Greece"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9701-8538","authenticated-orcid":false,"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto , Alameda Prof. Hern\u00e2ni Monteiro, Porto 4200-319 ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-5461","authenticated-orcid":false,"given":"Pedro","family":"Marques","sequence":"additional","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto , Alameda Prof. Hern\u00e2ni Monteiro, Porto 4200-319 ,","place":["Portugal"]}]},{"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto , Alameda Prof. Hern\u00e2ni Monteiro, Porto 4200-319 ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8683","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center, Baylor Heart and Vascular Institute , Dallas, TX ,","place":["USA"]},{"name":"Imperial College , London ,","place":["UK"]}]}],"member":"286","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2026031220165108300_xuag054-B1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031220165108300_xuag054-B2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031220165108300_xuag054-B3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/circulationaha.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026031220165108300_xuag054-B4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026031220165108300_xuag054-B5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1161\/circulationaha.122.061183","article-title":"Severe infection and risk of cardiovascular disease: a multicohort study","volume":"147","author":"Sipil\u00e4","year":"2023","journal-title":"Circulation"},{"key":"2026031220165108300_xuag054-B6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf788","article-title":"Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients","author":"Wu","year":"2025","journal-title":"Eur Heart J"},{"key":"2026031220165108300_xuag054-B7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.cardfail.2024.04.009","article-title":"Sodium-glucose cotransporter 2 inhibitors and mycotic genital or urinary tract infections in heart failure","volume":"30","author":"Duvalyan","year":"2024","journal-title":"J Card Fail"},{"key":"2026031220165108300_xuag054-B8","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ejhf.2065","article-title":"Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026031220165108300_xuag054-B9","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and Major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031220165108300_xuag054-B10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/ejhf.3180","article-title":"Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: an EMPEROR-preserved analysis","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026031220165108300_xuag054-B11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026031220165108300_xuag054-B12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026031220165108300_xuag054-B13","doi-asserted-by":"publisher","first-page":"e43245","DOI":"10.1097\/md.0000000000043245","article-title":"Risk factors of urinary tract infections with sodium-glucose cotransporter-2 inhibitors in heart failure","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"2026031220165108300_xuag054-B14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/s0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"2026031220165108300_xuag054-B15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1053\/j.ajkd.2004.04.040","article-title":"Late urinary tract infection after renal transplantation in the United States","volume":"44","author":"Abbott","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2026031220165108300_xuag054-B16","doi-asserted-by":"publisher","first-page":"106396","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026031220165108300_xuag054-B17","doi-asserted-by":"publisher","first-page":"109816","DOI":"10.1016\/j.diabres.2022.109816","article-title":"Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study","volume":"186","author":"Lin","year":"2022","journal-title":"Diabetes Res Clin Pract"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag054\/67175287\/xuag054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag054\/67175287\/xuag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:16:56Z","timestamp":1773361016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag054\/8502215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag054","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"article-number":"xuag054"}}